GEN-MKT-18-7897-A
Aug 5, 2015 | Blogs, Food / Beverage | 0 comments
Did you know that even though most of the world is covered in water, access to clean drinkingwater remains a problem? Take Asia for example where 62,000 people have lost their lives between 2001 and 2005 due to water-related disaster and illness.
Clean water is easier said than done, however, as more than a thousand chemical contaminants threaten our supply. Commercial waste, runoff and groundwater discharge including pollution from human waste, industrial use, and agriculture remain a problem. How then can we help world health organizations get a better handle on this epidemic? Improved sanitation helps, but so too does more advanced testing technology and SCIEX is in on the solution. A recent study by our scientists experimented with sample preparation and data processing according to EPA Method 537.
Want to Know Which Method for Testing Water Quality Came out on Top? Hands-down, it is mass spectrometry (MS) because of its ability to detect very low levels of a variety of chemical compounds. These range from pesticides and pharmaceuticals and personal care products (PPCP) to residual explosives and disinfection by-products.
A single test, just one, is all it takes to discover what lurks in drinking water when using MS. Imagine how many people could be saved from water-borne illnesses if world health organizations were able to adopt more advanced technology. If you are someone who is interested in uncovering how mass spectrometry can help advance water testing or know someone who is, read the full report.
Read About Additional Water Studies >
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
CE‑SDS remains a cornerstone assay for characterizing fragmentation, aggregation, and product‑related impurities in therapeutic proteins. UV detection has been the long‑standing standard. However, it frequently struggles with baseline noise, limited sensitivity for minor fragments, and subjective integration.
At SCIEX, innovation doesn’t stop at instruments; it extends to how you interact with your LC-MS/MS or CE systems every day. That’s why we’re excited to introduce the SCIEX Now spring 2026 improvements: a set of meaningful enhancements shaped directly by your feedback.
Posted by
You must be logged in to post a comment.
Share this post with your network